source
- Disc Medicine’s Phase 3 data revives rejected rare‑disease drug as China tightens biotech ownership rulesDisc Medicine announced that its Phase 3 trial of a previously rejected rare‑disease therapy showed positive results, effectively rescuing the program and positioning it for another submission to t…
- Arcus kidney cancer drug shows stronger potency than Merck's Welireg, boosting sharesArcus Biosciences reported follow‑up data from its late‑stage kidney cancer trial that suggest its experimental therapy, casdatifan, may be more potent than Merck's approved drug Welireg. Analysts…